Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 8;22(3):21.
doi: 10.1007/s11864-021-00821-8.

Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA

Sarah M Dermody  1 , Catherine T Haring  1 , Chandan Bhambhani  2 , Muneesh Tewari  2   3 , J Chad Brenner  1 , Paul L Swiecicki  4   5
Affiliations
Review

Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA

Sarah M Dermody et al. Curr Treat Options Oncol. .

Abstract

Human papilloma virus (HPV) related head and neck cancer is rising in prevalence, preferentially affecting young patients and imparting long term toxicities. Despite this, there are no screening tests or clinical biomarkers for treatment monitoring. HPV circulating tumor DNA (HPV ctDNA) represents a novel circulating biomarker which may provide real-time assessment of tumor response to therapy and recurrence. Early work suggests the promise of this assay as a predictive biomarker in numerous clinical settings, namely risk of recurrence after chemoradiation in locally advanced disease. Advancement of these findings to the clinic will require a collaborative effort in the field, including technical harmonization of assay testing characteristics, understanding of the normal kinetics in patients being treated with standard of care therapies, and appropriately designed phase III trials prior to implementation in the clinic. If successful, HPV ctDNA has the potential to revolutionize clinical trial treatment paradigms and transform patient care.

Keywords: Biomarker; HPV; Head and neck cancer; Oropharyngeal cancer; ctDNA.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E, and Urken ML. Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study. J Oral Maxillofac Surg. 2017;75(12):2562–2572. Epub 2017 May 22. doi: 10.1016/j.joms.2017.05.008. - DOI - PMC - PubMed
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al.Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin Oncol. 2011;29(32):4294–4301. doi: 10.1200/JCO.2011.36.4596. - DOI - PMC - PubMed
    1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al.Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. doi: 10.1056/NEJMoa0912217. - DOI - PMC - PubMed
    1. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al.Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–269. doi: 10.1093/jnci/djn011. - DOI - PubMed
    1. Mirghani H, Lang Kuhs KA, Waterboer T. Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer. Oral Oncol. 2018July;82:108–114. doi: 10.1016/j.oraloncology.2018.05.015. Epub 2018 May 21. - DOI - PubMed

MeSH terms

LinkOut - more resources